Jones Jeffrey Alan 4

What Happened Jeffrey Alan Jones, Chief Medical Officer of Cullinan Therapeutics (CGEM), was granted a derivative award of 300,000 shares on February 18, 2026. The reported acquisition price is $0.00 (total $0 reported), indicating an equity award/option rather than an open-market purchase or sale. This is a grant of compensation equity — not an immediate sale or cash purchase.

Key Details

• Transaction date: 2026-02-18; filing date: 2026-02-19 (appears filed promptly).
• Award: 300,000 shares reported at $0.00 (derivative award/option style).
• Vesting: The shares underlying the option vest over four years, with 1/48th vesting in equal monthly installments until the fourth anniversary of the grant date (Footnote F1).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing timeliness: No late-filing flag indicated in the provided data; filed the day after the grant.

Context This was a standard executive equity grant (derivative award) used for compensation/retention; it does not involve an immediate market purchase or sale and therefore is not a direct bullish or bearish trading signal. Vesting is monthly over four years, so economic benefit to the insider will accrue only as portions vest and any applicable exercise/transfer conditions are met.